论文部分内容阅读
Objective To evaluate milrinone with low molecular weight heparin on pulmonary heart disease.Method One hundred and twenty patients of pulmonary heart disease were divided into four groups randomly: control group, low molecular weight heparin, milrinone group, the combined treatment group.Each group was given conventional therapy.On this basis, low molecular weight heparin group treated with low molecular weight heparin; milrinone group treated with intravenous infusion of milrinone; combined treatment group treated with intravenous infusion of milrinone and low molecular heparin.Before treatment and 10 days after treatment, analysis results of Ddimer, blood gas analysis and lung function changes.Results Ten days after treatment Ddimer, arterjal pressure of carbon dioxide (PaCO2) in the combined treatment group were lower than those in milrinone group, low molecular weight heparin group and control group\ [(0.72±0.34) mg/L vs (0.87±0.46) mg/L, (0.85±0.28) mg/L, (0.99±0.38) mg/L; (48±9) mmHgvs (52±7) mmHg, (53±10) mmHg, (57±7) mmHg\] ; partial pressure of oxygen (PaO2), FEV 1 / predicted and FEV 1/forced vital capacity (FVC) were higher than those in milrinone group, low molecular weight heparin group and control group\[(73±5) mmHg vs (66±6) mmHg, (67±6) mmHg , (56±6) mmHg; (89±13) vs (75±8) (77±7), (69±10); (98±9) vs (81±10) , (79±8) , (71±7) \].Butmilrinone group and low molecular weight heparin no significant difference in the indicators.Conclusion Milrinone with low molecular weight heparin can reduce pulmonary arterial pressure and improve the ability of tissue to uptake and use oxygen, which can improve symptoms and signs significantly, has positive effect on improving clinical outcomes and reduce mortality.